Report of Foreign Issuer (6-k)
July 14 2017 - 4:48PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act
of 1934
For the month of July 2017
Commission File Number: 001-37643
KITOV
PHARMACEUTICALS HOLDINGS LTD.
(Translation of registrant’s name into English)
One Azrieli Center,
Round Tower, 23rd Floor, Tel Aviv 6701101, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate by check mark if the Registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the Registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Attached hereto and incorporated by reference
herein are the following exhibits:
Exhibit 1.1: Form of Securities Purchase Agreement dated as of July 11, 2017 by and between the Registrant and the purchasers in the offering.
Exhibit 1.2: Engagement Agreement, dated July 6, 2017 between the Registrant and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (“Rodman”).
Exhibit 4.1: Form of Warrant issued to purchasers in the offering.
Exhibit 4.2: Form of Placement Agent Warrant issued to Rodman.
Exhibit 5.1: Opinion of Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co.
Exhibit 5.2: Opinion of Haynes and Boone, LLP
Exhibit 23.1: Consent of Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co. (included in Exhibit 5.1).
Exhibit 23.2: Consent of Haynes and Boone, LLP (included in Exhibit 5.2).
This Form 6-K shall not constitute an
offer to sell or the solicitation of an offer to buy, nor shall there be any sale of ADSs or warrants in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
jurisdiction.
This Form 6-K is incorporated by reference
into each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on December
12, 2016 (Registration file numbers 333-207117, 333-211477 and 333-215037), the Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), and the Registrant’s
Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number
333-218538).
2
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
KITOV PHARMACEUTICALS HOLDINGS LTD.
|
|
|
|
By:
|
/s/ Isaac Israel
|
Date: July 14, 2017
|
|
Isaac Israel
Chief Executive Officer
|
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Apr 2023 to Apr 2024